Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 7—July 2011

CME ACTIVITY - Research

Hantavirus Pulmonary Syndrome, United States, 1993–2009

Adam MacNeilComments to Author , Thomas G. Ksiazek, and Pierre E. Rollin
Author affiliations: Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (A. MacNeil, T.G. Ksiazek, P.E. Rollin); and University of Texas Medical Branch, Galveston, Texas, USA (T.G. Ksiazek)

Main Article

Table 3

Clinical characteristics of HPS case-patients, United States, 1993–2009*

Characteristic No. patients reporting characteristic/no. patients for whom data were available for that characteristic (%)
p value†
All Died Survived
Fever 356/397 (90) 116/132 (88) 239/264 (91) 0.414
Thrombocytopenia‡ 405/418 (97) 131/134 (98) 273/283 (96) 0.477
Increased hematocrit‡ 261/389 (67) 103/130 (79) 157/258 (61) <0.001
Increased creatinine level‡ 120/286 (42) 54/93 (58) 66/193 (34) <0.001
Increased leukocyte count‡ 169/234 (72) 72/83 (87) 96/150 (64) <0.001
Chest radiograph showing unexplained bilateral infiltrates or suggestive of ARDS 390/406 (96) 135/141 (96) 255/265 (96) 0.812
Need for supplemental oxygen 390/405 (96) 134/135 (99) 255/269 (95) 0.025
Intubation of patient 265/430 (62) 129/139 (93) 135/290 (47) <0.001

*HPS, hantavirus pulmonary syndrome; ARDS, acute respiratory distress syndrome.
†By χ2 test for difference in the proportion of HPS case-patients with a clinical characteristic who died and those who survived.
‡Based on qualitative data (yes or no) regarding clinical characteristic from case investigation form. For a small number of case-patients for whom qualitative data were incomplete, but for whom laboratory values were available, qualitative values were assigned on the basis of described clinical cutoff values (24).

Main Article

TOP